Virus-like particles displaying trimeric simian immunodeficiency virus (SIV) envelope gp160 enhance the breadth of DNA/modified vaccinia virus Ankara SIV vaccine-induced antibody responses in rhesus macaques

Smita Iyer, Sailaja Gangadhara, Blandine Victor, Xiaoying Shen, Xuemin Chen, Rafiq Nabi, Sudhir P. Kasturi, Michael J. Sabula, Celia C. Labranche, Pradeep B.J. Reddy, Georgia D. Tomaras, David C. Montefiori, Bernard Moss, Paul Spearman, Bali Pulendran, Pamela A. Kozlowski, Rama Rao Amara

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The encouraging results of the RV144 vaccine trial have spurred interest in poxvirus prime-protein boost human immunodeficiency virus (HIV) vaccine modalities as a strategy to induce protective immunity. Because vaccine-induced protective immunity is critically determined by HIV envelope (Env) conformation, significant efforts are directed toward generating soluble trimeric Env immunogens that assume native structures. Using the simian immunodeficiency virus (SIV)-macaque model, we tested the immunogenicity and efficacy of sequential immunizations withDNA(D), modified vaccinia virus Ankara (MVA) (M), and protein immunogens, all expressing virus-like particles (VLPs) displaying membrane-anchored trimeric Env. A single VLP protein boost displaying trimeric gp160 adjuvanted with nanoparticle-encapsulated Toll-like receptor 4/7/8 (TLR4/7/8) agonists, administered 44 weeks after the secondMVA immunization, induced up to a 3-fold increase in Env-specific IgG binding titers in serum and mucosa. Importantly, the VLP protein boost increased binding antibody against scaffolded V1V2, antibody-dependent phagocytic activity against VLP-coated beads, and antibody breadth and neutralizing antibody titers against homologous and heterologous tier 1 SIVs. Following 5 weekly intrarectal SIVmac251 challenges, two of sevenDNA/MVAand VLP (DM+VLP)-vaccinated animals were completely protected compared to productive infection in all seven DM-vaccinated animals. Vaccinated animals demonstrated stronger acute viral pulldown than controls, but a trend for higher acute viremia was observed in the DM+VLP group, likely due to a slower recall of Gag-specific CD8 T cells. Our findings support immunization with VLPs containing trimeric Env as a strategy to augment protective antibody but underscore the need for optimal engagement of CD8 T cells to achieve robust early viral control.

Original languageEnglish (US)
Pages (from-to)8842-8854
Number of pages13
JournalJournal of Virology
Volume90
Issue number19
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Simian immunodeficiency virus
Simian Immunodeficiency Virus
Vaccinia virus
virus-like particles
Macaca mulatta
Virion
Antibody Formation
Vaccines
vaccines
antibodies
DNA
Immunization
immunization
Antibodies
Human immunodeficiency virus
Immunity
proteins
T-lymphocytes
immunity
Toll-Like Receptor 7

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Insect Science
  • Virology

Cite this

Virus-like particles displaying trimeric simian immunodeficiency virus (SIV) envelope gp160 enhance the breadth of DNA/modified vaccinia virus Ankara SIV vaccine-induced antibody responses in rhesus macaques. / Iyer, Smita; Gangadhara, Sailaja; Victor, Blandine; Shen, Xiaoying; Chen, Xuemin; Nabi, Rafiq; Kasturi, Sudhir P.; Sabula, Michael J.; Labranche, Celia C.; Reddy, Pradeep B.J.; Tomaras, Georgia D.; Montefiori, David C.; Moss, Bernard; Spearman, Paul; Pulendran, Bali; Kozlowski, Pamela A.; Amara, Rama Rao.

In: Journal of Virology, Vol. 90, No. 19, 01.01.2016, p. 8842-8854.

Research output: Contribution to journalArticle

Iyer, S, Gangadhara, S, Victor, B, Shen, X, Chen, X, Nabi, R, Kasturi, SP, Sabula, MJ, Labranche, CC, Reddy, PBJ, Tomaras, GD, Montefiori, DC, Moss, B, Spearman, P, Pulendran, B, Kozlowski, PA & Amara, RR 2016, 'Virus-like particles displaying trimeric simian immunodeficiency virus (SIV) envelope gp160 enhance the breadth of DNA/modified vaccinia virus Ankara SIV vaccine-induced antibody responses in rhesus macaques', Journal of Virology, vol. 90, no. 19, pp. 8842-8854. https://doi.org/10.1128/JVI.01163-16
Iyer, Smita ; Gangadhara, Sailaja ; Victor, Blandine ; Shen, Xiaoying ; Chen, Xuemin ; Nabi, Rafiq ; Kasturi, Sudhir P. ; Sabula, Michael J. ; Labranche, Celia C. ; Reddy, Pradeep B.J. ; Tomaras, Georgia D. ; Montefiori, David C. ; Moss, Bernard ; Spearman, Paul ; Pulendran, Bali ; Kozlowski, Pamela A. ; Amara, Rama Rao. / Virus-like particles displaying trimeric simian immunodeficiency virus (SIV) envelope gp160 enhance the breadth of DNA/modified vaccinia virus Ankara SIV vaccine-induced antibody responses in rhesus macaques. In: Journal of Virology. 2016 ; Vol. 90, No. 19. pp. 8842-8854.
@article{70a5a923867f43c69bfb57d9fe6b9484,
title = "Virus-like particles displaying trimeric simian immunodeficiency virus (SIV) envelope gp160 enhance the breadth of DNA/modified vaccinia virus Ankara SIV vaccine-induced antibody responses in rhesus macaques",
abstract = "The encouraging results of the RV144 vaccine trial have spurred interest in poxvirus prime-protein boost human immunodeficiency virus (HIV) vaccine modalities as a strategy to induce protective immunity. Because vaccine-induced protective immunity is critically determined by HIV envelope (Env) conformation, significant efforts are directed toward generating soluble trimeric Env immunogens that assume native structures. Using the simian immunodeficiency virus (SIV)-macaque model, we tested the immunogenicity and efficacy of sequential immunizations withDNA(D), modified vaccinia virus Ankara (MVA) (M), and protein immunogens, all expressing virus-like particles (VLPs) displaying membrane-anchored trimeric Env. A single VLP protein boost displaying trimeric gp160 adjuvanted with nanoparticle-encapsulated Toll-like receptor 4/7/8 (TLR4/7/8) agonists, administered 44 weeks after the secondMVA immunization, induced up to a 3-fold increase in Env-specific IgG binding titers in serum and mucosa. Importantly, the VLP protein boost increased binding antibody against scaffolded V1V2, antibody-dependent phagocytic activity against VLP-coated beads, and antibody breadth and neutralizing antibody titers against homologous and heterologous tier 1 SIVs. Following 5 weekly intrarectal SIVmac251 challenges, two of sevenDNA/MVAand VLP (DM+VLP)-vaccinated animals were completely protected compared to productive infection in all seven DM-vaccinated animals. Vaccinated animals demonstrated stronger acute viral pulldown than controls, but a trend for higher acute viremia was observed in the DM+VLP group, likely due to a slower recall of Gag-specific CD8 T cells. Our findings support immunization with VLPs containing trimeric Env as a strategy to augment protective antibody but underscore the need for optimal engagement of CD8 T cells to achieve robust early viral control.",
author = "Smita Iyer and Sailaja Gangadhara and Blandine Victor and Xiaoying Shen and Xuemin Chen and Rafiq Nabi and Kasturi, {Sudhir P.} and Sabula, {Michael J.} and Labranche, {Celia C.} and Reddy, {Pradeep B.J.} and Tomaras, {Georgia D.} and Montefiori, {David C.} and Bernard Moss and Paul Spearman and Bali Pulendran and Kozlowski, {Pamela A.} and Amara, {Rama Rao}",
year = "2016",
month = "1",
day = "1",
doi = "10.1128/JVI.01163-16",
language = "English (US)",
volume = "90",
pages = "8842--8854",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "19",

}

TY - JOUR

T1 - Virus-like particles displaying trimeric simian immunodeficiency virus (SIV) envelope gp160 enhance the breadth of DNA/modified vaccinia virus Ankara SIV vaccine-induced antibody responses in rhesus macaques

AU - Iyer, Smita

AU - Gangadhara, Sailaja

AU - Victor, Blandine

AU - Shen, Xiaoying

AU - Chen, Xuemin

AU - Nabi, Rafiq

AU - Kasturi, Sudhir P.

AU - Sabula, Michael J.

AU - Labranche, Celia C.

AU - Reddy, Pradeep B.J.

AU - Tomaras, Georgia D.

AU - Montefiori, David C.

AU - Moss, Bernard

AU - Spearman, Paul

AU - Pulendran, Bali

AU - Kozlowski, Pamela A.

AU - Amara, Rama Rao

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The encouraging results of the RV144 vaccine trial have spurred interest in poxvirus prime-protein boost human immunodeficiency virus (HIV) vaccine modalities as a strategy to induce protective immunity. Because vaccine-induced protective immunity is critically determined by HIV envelope (Env) conformation, significant efforts are directed toward generating soluble trimeric Env immunogens that assume native structures. Using the simian immunodeficiency virus (SIV)-macaque model, we tested the immunogenicity and efficacy of sequential immunizations withDNA(D), modified vaccinia virus Ankara (MVA) (M), and protein immunogens, all expressing virus-like particles (VLPs) displaying membrane-anchored trimeric Env. A single VLP protein boost displaying trimeric gp160 adjuvanted with nanoparticle-encapsulated Toll-like receptor 4/7/8 (TLR4/7/8) agonists, administered 44 weeks after the secondMVA immunization, induced up to a 3-fold increase in Env-specific IgG binding titers in serum and mucosa. Importantly, the VLP protein boost increased binding antibody against scaffolded V1V2, antibody-dependent phagocytic activity against VLP-coated beads, and antibody breadth and neutralizing antibody titers against homologous and heterologous tier 1 SIVs. Following 5 weekly intrarectal SIVmac251 challenges, two of sevenDNA/MVAand VLP (DM+VLP)-vaccinated animals were completely protected compared to productive infection in all seven DM-vaccinated animals. Vaccinated animals demonstrated stronger acute viral pulldown than controls, but a trend for higher acute viremia was observed in the DM+VLP group, likely due to a slower recall of Gag-specific CD8 T cells. Our findings support immunization with VLPs containing trimeric Env as a strategy to augment protective antibody but underscore the need for optimal engagement of CD8 T cells to achieve robust early viral control.

AB - The encouraging results of the RV144 vaccine trial have spurred interest in poxvirus prime-protein boost human immunodeficiency virus (HIV) vaccine modalities as a strategy to induce protective immunity. Because vaccine-induced protective immunity is critically determined by HIV envelope (Env) conformation, significant efforts are directed toward generating soluble trimeric Env immunogens that assume native structures. Using the simian immunodeficiency virus (SIV)-macaque model, we tested the immunogenicity and efficacy of sequential immunizations withDNA(D), modified vaccinia virus Ankara (MVA) (M), and protein immunogens, all expressing virus-like particles (VLPs) displaying membrane-anchored trimeric Env. A single VLP protein boost displaying trimeric gp160 adjuvanted with nanoparticle-encapsulated Toll-like receptor 4/7/8 (TLR4/7/8) agonists, administered 44 weeks after the secondMVA immunization, induced up to a 3-fold increase in Env-specific IgG binding titers in serum and mucosa. Importantly, the VLP protein boost increased binding antibody against scaffolded V1V2, antibody-dependent phagocytic activity against VLP-coated beads, and antibody breadth and neutralizing antibody titers against homologous and heterologous tier 1 SIVs. Following 5 weekly intrarectal SIVmac251 challenges, two of sevenDNA/MVAand VLP (DM+VLP)-vaccinated animals were completely protected compared to productive infection in all seven DM-vaccinated animals. Vaccinated animals demonstrated stronger acute viral pulldown than controls, but a trend for higher acute viremia was observed in the DM+VLP group, likely due to a slower recall of Gag-specific CD8 T cells. Our findings support immunization with VLPs containing trimeric Env as a strategy to augment protective antibody but underscore the need for optimal engagement of CD8 T cells to achieve robust early viral control.

UR - http://www.scopus.com/inward/record.url?scp=84990226849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990226849&partnerID=8YFLogxK

U2 - 10.1128/JVI.01163-16

DO - 10.1128/JVI.01163-16

M3 - Article

VL - 90

SP - 8842

EP - 8854

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 19

ER -